Voyager Therapeutics (VYGR) Equity Average: 2015-2025
Historic Equity Average for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $231.9 million.
- Voyager Therapeutics' Equity Average fell 30.34% to $231.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.9 million, marking a year-over-year decrease of 30.34%. This contributed to the annual value of $268.0 million for FY2024, which is 81.51% up from last year.
- As of Q3 2025, Voyager Therapeutics' Equity Average stood at $231.9 million, which was down 10.23% from $258.3 million recorded in Q2 2025.
- Over the past 5 years, Voyager Therapeutics' Equity Average peaked at $338.2 million during Q2 2024, and registered a low of $68.0 million during Q2 2022.
- For the 3-year period, Voyager Therapeutics' Equity Average averaged around $253.7 million, with its median value being $258.3 million (2025).
- Per our database at Business Quant, Voyager Therapeutics' Equity Average crashed by 44.89% in 2022 and then spiked by 205.91% in 2023.
- Voyager Therapeutics' Equity Average (Quarterly) stood at $91.2 million in 2021, then dropped by 23.91% to $69.4 million in 2022, then skyrocketed by 197.13% to $206.3 million in 2023, then spiked by 52.73% to $315.0 million in 2024, then slumped by 30.34% to $231.9 million in 2025.
- Its Equity Average was $231.9 million in Q3 2025, compared to $258.3 million in Q2 2025 and $286.2 million in Q1 2025.